{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:10:53Z","timestamp":1790543453124,"version":"4.1.0"},"reference-count":107,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2016]]},"DOI":"10.3960\/jslrt.56.1","type":"journal-article","created":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T19:29:00Z","timestamp":1466623740000},"page":"1-19","source":"Crossref","is-referenced-by-count":46,"title":["Follicular Lymphoma: The Role of the Tumor Microenvironment in Prognosis"],"prefix":"10.3960","volume":"56","author":[{"given":"Takumi","family":"Sugimoto","sequence":"first","affiliation":[{"name":"Hematology Division, Komaki City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Hematology Division, Komaki City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Izumo T, Maseki N, Mori S, Tsuchiya E: Practical utility of the revised European-American classification of lymphoid neoplasms for Japanese non-Hodgkin\u2019s lymphomas. Jpn J Cancer Res 91:351-360, 2000","DOI":"10.1111\/j.1349-7006.2000.tb00952.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Roulland S, Faroudi M, Mamessier E, Sungalee S, Salles G, <i>et al<\/i>.: Early steps of follicular lymphoma pathogenesis. Adv Immunol 111:1-46, 2011","DOI":"10.1016\/B978-0-12-385991-4.00001-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, <i>et al<\/i>.: Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476:298-303, 2011","DOI":"10.1038\/nature10351"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, <i>et al<\/i>.: The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell 147:554-564, 2011","DOI":"10.1016\/j.cell.2011.09.035"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Cheung KJ, Johnson NA, Affleck JG, Severson T, Steidl C, <i>et al<\/i>.: Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res 70:9166-9174, 2010","DOI":"10.1158\/0008-5472.CAN-10-2460"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Launay E, Pangault C, Bertrand P, Jardin F, Lamy T, <i>et al<\/i>.: High rate of TNFRSF14 gene alterations related to 1p36 region in <i>de novo<\/i> follicular lymphoma and impact on prognosis. Leukemia 26:559-562, 2012","DOI":"10.1038\/leu.2011.266"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, <i>et al<\/i>.: Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42:181-185, 2010","DOI":"10.1038\/ng.518"},{"key":"8","unstructured":"8 Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, <i>et al<\/i>.: Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 13:140-147, 1995"},{"key":"9","unstructured":"9 Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, <i>et al<\/i>.: Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 31:3272-3278, 2013"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Conconi A, Ponzio C, Lobetti-Bodoni C, Motta M, Rancoita PM, <i>et al<\/i>.: Incidence, risk factors and outcome of histologic transformation in follicular lymphoma. Br J Haematol 157:188-196, 2012","DOI":"10.1111\/j.1365-2141.2012.09054.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, <i>et al<\/i>.: Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 17:2426-2433, 2007","DOI":"10.1200\/JCO.2006.09.3260"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Abramson JS, Zelenetz AD: Recent advances in the treatment of non-Hodgkin\u2019s lymphomas. J Natl Compr Canc Netw 11 (5 Suppl):671-675, 2013","DOI":"10.6004\/jnccn.2013.0198"},{"key":"13","unstructured":"13 Bastion Y, Berger F, Bryon PA, Felman P, Ffrench M, <i>et al<\/i>.: Follicular lymphomas: Assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 2 (Suppl 2):123-129, 1991"},{"key":"14","unstructured":"14 Leonard RC, Hayward RL, Prescott RJ, Wang JX: The identification of discrete prognostic groups in low grade non-Hodgkin\u2019s lymphoma: The Scotland and Newcastle Lymphoma Group Therapy Working Party. Ann Oncol 2:655-662, 1991"},{"key":"15","unstructured":"15 Decaudin D, Lepage E, Brousse N, Brice P, Harousseau JL, <i>et al<\/i>.: Low-grade stage III-IV follicular lymphoma: Multivariate analysis of prognostic factors in 484 patients \u2013 a study of the groupe d\u2019Etude des lymphomes de l\u2019Adulte. J Clin Oncol 17:2499-2505, 1999"},{"key":"16","unstructured":"16 Federico M, Vitolo U, Zinzani PL, Chisesi T, Cl\u00f2 V, <i>et al<\/i>.: Prognosis of follicular lymphoma: A predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 95:783-789, 2000"},{"key":"17","unstructured":"17 Federico M, Guglielmi C, Luminari S, Mammi C, Marcheselli L, <i>et al<\/i>.: Prognostic relevance of serum \u03b22 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens: A GISL study. Haematologica 92:1482-1488, 2007"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Solal-C\u00e9ligny P, Roy P, Colombat P, White J, Armitage JO, <i>et al<\/i>.: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004","DOI":"10.1182\/blood-2003-12-4434"},{"key":"19","unstructured":"19 Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, <i>et al<\/i>.: Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27:4555-4562, 2009"},{"key":"20","unstructured":"20 Sander B, de Jong D, Rosenwald A, Xie W, Balagu\u00e9 O, <i>et al<\/i>.: The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. Haematologica 99:715-725, 2014"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Kridel R, Sehn LH, Gascoyne RD: Pathogenesis of follicular lymphoma. J Clin Invest 122:3424-3431, 2012","DOI":"10.1172\/JCI63186"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, <i>et al<\/i>.: Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin\u2019s Lymphoma. J Clin Oncol 27:5404-5409, 2009","DOI":"10.1200\/JCO.2008.21.1169"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Wu L, Adams M, Carter T, Chen R, Muller G, <i>et al<\/i>.: Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20<sup>+<\/sup> tumor cells. Clin Cancer Res 14:4650-4657, 2008","DOI":"10.1158\/1078-0432.CCR-07-4405"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, <i>et al<\/i>.: Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab <i>in vivo<\/i>. Br J Haematol 140:36-45, 2007","DOI":"10.1111\/j.1365-2141.2007.06841.x"},{"key":"25","unstructured":"25 Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, <i>et al<\/i>.: Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15:1311-1318, 2014"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Tuscano JM, Dutia M, Chee K, Brunson A, Reed-Pease C, <i>et al<\/i>.: Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non- Hodgkin lymphoma. Br J Haematol 165:375-381, 2014","DOI":"10.1111\/bjh.12755"},{"key":"27","unstructured":"27 Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, <i>et al<\/i>.: Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 114:4713-4720, 2009"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Tilly H, Morschhauser F, Salles G, Casasnovas RO, Feugier P, <i>et al<\/i>.: Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia 27:252-255, 2013","DOI":"10.1038\/leu.2012.172"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, <i>et al<\/i>.: Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 15:6446-6453, 2009","DOI":"10.1158\/1078-0432.CCR-09-1339"},{"key":"30","unstructured":"30 Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, <i>et al<\/i>.: Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15:69-77, 2014"},{"key":"31","unstructured":"31 Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, <i>et al<\/i>.: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159-2169, 2004"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 \u00c1lvaro T, Lejeune M, Salvad\u00f3 MT, Lopez C, Ja\u00e9n J, <i>et al<\/i>.: Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 24:5350-5357, 2006","DOI":"10.1200\/JCO.2006.06.4766"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Wahlin BE, Sander B, Christensson B, Kimby E: CD8<sup>+<\/sup> T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 13:388-397, 2007","DOI":"10.1158\/1078-0432.CCR-06-1734"},{"key":"34","unstructured":"34 Laurent C, M\u00fcller S, Do C, Al-Saati T, Allart S, <i>et al<\/i>.: Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. Blood 118:5371-5379, 2011"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Lee AM, Clear AJ, Calaminici M, Davies AJ, Jordan S, <i>et al<\/i>.: Number of CD4<sup>+<\/sup> cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 24:5052-5059, 2006","DOI":"10.1200\/JCO.2006.06.4642"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, <i>et al<\/i>.: Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 106:2169-2174, 2005","DOI":"10.1182\/blood-2005-04-1565"},{"key":"37","unstructured":"37 Kiaii S, Clear AJ, Ramsay AG, Davies D, Sangaralingam A, <i>et al<\/i>.: Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J Clin Oncol 31:2654-2661, 2013"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Yang Z-Z, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM: Attenuation of CD8<sup>+<\/sup> T-cell function by CD4<sup>+<\/sup>CD25<sup>+<\/sup> regulatory T cells in B-cell non-Hodgkin\u2019s lymphoma. Cancer Res 66:10145-10152, 2006","DOI":"10.1158\/0008-5472.CAN-06-1822"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, <i>et al<\/i>.: High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108:2957-2964, 2006","DOI":"10.1182\/blood-2006-04-018218"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, <i>et al<\/i>.: Correlation of high numbers of intratumoral FOXP3<sup>+<\/sup> regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin\u2019s lymphoma. Haematologica 93:193-200, 2008","DOI":"10.3324\/haematol.11702"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Carreras J, Lopez-Guillermo A, Roncador G, Villamor N, Colomo L, <i>et al<\/i>.: High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 27:1470-1476, 2009","DOI":"10.1200\/JCO.2008.18.0513"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 de Jong D, Koster A, Hagenbeek A, Raemaekers D, Veldhuizen D, <i>et al<\/i>.: Impact of the tumor microenvironment of prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 94:70-77, 2009","DOI":"10.3324\/haematol.13574"},{"key":"43","unstructured":"43 Sweetenham JW, Goldman B, LeBlanc ML, Cook JR, Tubbs RR, <i>et al<\/i>.: Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the induction of monoclonal antibody therapy: a Southwest Oncology Group Study. Ann Oncol 21:1196-1202, 2010"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, <i>et al<\/i>.: The architectural pattern of FOXP3-possitive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood 115:289-295, 2010","DOI":"10.1182\/blood-2009-07-235598"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Chen W, Jin W, Hardegen N, Lei KJ, Li L, <i>et al<\/i>.: Conversion of peripheral CD4<sup>+<\/sup>CD25<sup>-<\/sup> naive T cells to CD4<sup>+<\/sup>CD25<sup>+<\/sup> regulatory T cells by TGF-\u03b2 induction of transcription factor Foxp3. J Exp Med 198:1875-1886, 2003","DOI":"10.1084\/jem.20030152"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA: Natural and induced CD4<sup>+<\/sup>CD25<sup>+<\/sup> cells educate CD4<sup>+<\/sup>CD25<sup>-<\/sup> cells to develop suppressive activity: the role of IL-2, TGF-\u03b2, and IL-10. J Immunol 172:5213-5221, 2004","DOI":"10.4049\/jimmunol.172.9.5213"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, <i>et al<\/i>.: Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4<sup>+<\/sup>CD25<sup>-<\/sup> T cells. J Clin Invest 112:1437-1443, 2003","DOI":"10.1172\/JCI200319441"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Nishioka T, Shimizu J, Iida R, Yamazaki S, Sakaguchi S: CD4<sup>+<\/sup>CD25<sup>+<\/sup>Foxp3<sup>+<\/sup> T cells and CD4<sup>+<\/sup>CD25<sup>-<\/sup>Foxp3<sup>+<\/sup> T cells in aged mice. J Immunol 176:6586-6593, 2006","DOI":"10.4049\/jimmunol.176.11.6586"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Yang Z-Z, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM: CD70<sup>+<\/sup> non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4<sup>+<\/sup>CD25<sup>-<\/sup> T cells. Blood 110:2537-2544, 2007","DOI":"10.1182\/blood-2007-03-082578"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Linterman MA, Pierson W, Lee SK, Kallies A, Kawamoto S, et al.: Foxp3<sup>+<\/sup> follicular regulatory T cells control the germinal center response. Nat Med 17:975-982, 2011","DOI":"10.1038\/nm.2425"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Chung Y, Tanaka S, Chu F, Nurieva RI, Martinez GJ, <i>et al<\/i>.: Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med 17:983-988, 2011","DOI":"10.1038\/nm.2426"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Taskinen M, Karjalainen-Lindsberg M-L, Nyman H, Eerola L-M, Lepp\u00e4 S: A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vin-cristine-prednisone. Clin Cancer Res 13:5784-5789, 2007","DOI":"10.1158\/1078-0432.CCR-07-0778"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, <i>et al<\/i>.: High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 26:440-446, 2008","DOI":"10.1200\/JCO.2007.12.8298"},{"key":"54","unstructured":"54 \u00c1lvaro T, Lejeune M, Camacho FI, Salvad\u00f3 MT, S\u00e1nchez L, <i>et al<\/i>.: The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica 91:1605-1612, 2006"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Taskinen M, Karjalaninen-Lindsberg M-L, Lepp\u00e4 S: Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. Blood 111:4664-4667, 2008","DOI":"10.1182\/blood-2007-11-125823"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Crotty S: Follicular helper CD4 T cells (T<sub>FH<\/sub>). Annu Rev Immunol 29:621-663, 2011","DOI":"10.1146\/annurev-immunol-031210-101400"},{"key":"57","unstructured":"57 Pangault C, Am\u00e9-Thomas P, Ruminy P, Rossille D, Caron G, <i>et al<\/i>.: Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T<sub>FH<\/sub>-B cell axis. Leukemia 24:2080-2089, 2010"},{"key":"58","unstructured":"58 Am\u00e9-Thomas P, Maby-El Hajjami H, Monvoisin C, Jean R, Monnier D,, <i>et al<\/i>.: Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells on follicular lymphoma pathogenesis. Blood 109:693-702, 2007"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Guilloton F1, Caron G, M\u00e9nard C, Pangault C, Am\u00e9-Thomas P, <i>et al<\/i>.: Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood 119:2556-2567, 2012","DOI":"10.1182\/blood-2011-08-370908"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Glas AM, Knoops L, Delahaye L, Kersten MJ, Kibbelaar RE, <i>et al<\/i>.: Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 25:390-398, 2007","DOI":"10.1200\/JCO.2006.06.1648"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 Richendollar BG, Pohlman B, Elson P, Hsi ED.: Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Hum Pathol 42:552-557, 2011","DOI":"10.1016\/j.humpath.2010.08.015"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 Johnston RJ, Poholek AC, DiToro D, Yusuf I, Eto D, <i>et al<\/i>.: Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 325:1006-1010, 2009","DOI":"10.1126\/science.1175870"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 Ma CS, Suryani S, Avery DT, Chan A, Nanan R, <i>et al<\/i>.: Early commitment of na\u00efve human CD4<sup>+<\/sup> T cells to the T follicular helper (T<sub>FH<\/sub>) cell lineage is induced by IL-12. Immunol Cell Biol 87:590-600, 2009","DOI":"10.1038\/icb.2009.64"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Bauquet AT, Jin H, Paterson AM, Mitsdoerffer M, Ho IC, <i>et al<\/i>.: The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and T<sub>H<\/sub>-17 cells. Nat Immunol 10:167-175, 2009","DOI":"10.1038\/ni.1690"},{"key":"65","unstructured":"65 Am\u00e9-Thomas P, Le Priol J, Yssel H, Caron G, Pangault C, <i>et al<\/i>.: Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia 26:1053-1063, 2012"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Yang Z-Z, Grote DM, Ziesmer SC, Xiu B, Novak AJ, <i>et al<\/i>.: PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival. Blood Cancer J 5:e281, 2015","DOI":"10.1038\/bcj.2015.1"},{"key":"67","unstructured":"67 Xerri L, Bachy E, Fabiani B, Canioni D, Chassagne-Cl\u00e9ment C, <i>et al<\/i>.: Rituximab treatment in follicular lymphoma circumvents the prognostic value of intra-tumoural T-cells: automated image analysis of the LYSA PRIMA trial. Hematol Oncol 33 (Suppl S1):112, 2015 [Abstract 024]"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68 Smeltzer JP, Jones JM, Ziesmer SC, Grote DM, Xiu B, <i>et al<\/i>.: Pattern of CD14<sup>+<\/sup> follicular dendritic cells and PD1<sup>+<\/sup> T cells independently predicts time to transformation in follicular lym phoma. Clin Cancer Res 20:2862-2872, 2014","DOI":"10.1158\/1078-0432.CCR-13-2367"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69 Petrasch S, Perez-Alvarez C, Schmitz J, Kosco M, Brittinger G: Antigenic phenotyping of human follicular dendritic cells isolated from nonmalignant and malignant lymphatic tissue. Eur J Immunol 20:1013-1018, 1990","DOI":"10.1002\/eji.1830200510"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70 Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, <i>et al<\/i>.: Immunosuppressive CD14<sup>+<\/sup>HLA-DR<sup>low\/-<\/sup> monocytes in B-cell non-Hodgkin lymphoma. Blood 117:872-881, 2011","DOI":"10.1182\/blood-2010-05-283820"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Yang Z-Z, Grote DM, Ziesmer SC, Niki T, Hirashima M, <i>et al<\/i>.: IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 122:1271-1282, 2012","DOI":"10.1172\/JCI59806"},{"key":"72","unstructured":"72 Wahlin BE, Aggarwal M, Montes-Moreno S, Gonzalez LF, Roncador G, <i>et al<\/i>.: A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 16:637-650, 2010"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73 Farinha P, Roncador G, Al-Tourah A, Connors JM, Gascoyne RD: Combined FOXP3<sup>+<\/sup> and PD1<sup>+<\/sup> T cell density and architectural patterns predict overall survival and risk of transformation in uniformly treated patients with follicular lymphoma. Blood (ASH Annual Meeting Abstracts) 112:2815, 2008 [Abstract]","DOI":"10.1182\/blood.V112.11.2815.2815"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74 Mantovani A, Sozzani S, Locati M, Allavena P, Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549-555, 2002","DOI":"10.1016\/S1471-4906(02)02302-5"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75 Sica A, Mantovani A: Macrophage plasticity and polarization: <i>in vivo<\/i> veritas. J Clin Invest 122:787-795, 2012","DOI":"10.1172\/JCI59643"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76 Clear AJ, Lee AM, Calaminici M, Ramsay AG, Morris KJ, <i>et al<\/i>.: Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163<sup>+<\/sup> macrophages within the immediate sprouting microenvironment. Blood 115:5053-5056, 2010","DOI":"10.1182\/blood-2009-11-253260"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77 Farinha P, Kyle AH, Minchinton AI, Connors JM, Karsan A, <i>et al<\/i>.: Vascularization predicts overall survival and risk of transformation in follicular lymphoma. Haematologica 95:2157-2160, 2010","DOI":"10.3324\/haematol.2009.021766"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78 Yang Z-Z, Novak AJ, Stenson MJ, Witzig TE, Ansell SM: Intratumoral CD4<sup>+<\/sup>CD25<sup>+<\/sup> regulatory T-cell-mediated suppression of infiltrating CD4<sup>+<\/sup> T cells in B-cell non-Hodgkin lymphoma. Blood 107:3639-3646, 2006","DOI":"10.1182\/blood-2005-08-3376"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79 Ai WZ, Hou J-Z, Zeiser R, Czerwinski D, Negrin RS, <i>et al<\/i>.: Follicular lymphoma B cells induce the conversion of conventional CD4<sup>+<\/sup> T cells to T-regulatory cells. Int J Cancer 124:239-244, 2009","DOI":"10.1002\/ijc.23881"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80 Buechler C, Ritter M, Ors\u00f3 E, Langmann T, Klucken J, <i>et al<\/i>.: Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol 67:97-103, 2000","DOI":"10.1002\/jlb.67.1.97"},{"key":"81","unstructured":"81 Kridel R, Xerri L, Gelas-Dore B, Tan K, Feugier P, <i>et al<\/i>.: The prognostic impact of CD163-positive macrophages in follicular lymphoma: A study from the BC Cancer Agency and the Lymphoma Association. Clin Cancer Res 21:3428-3435, 2015"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82 De Palma M, Lewis CE: Macrophage regulation of tumor response to anticancer therapies. Cancer Cell 23:277-286, 2013","DOI":"10.1016\/j.ccr.2013.02.013"},{"key":"83","unstructured":"83 Mantovani A, Polentarutti N, Luini W, Peri G, Spreafico F: Role of host defense mechanisms in the antitumor activity of adriamycin and daunomycin in mice. J Natl Cancer Inst 63:61-66, 1979"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84 Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, <i>et al<\/i>.: Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38:729-741, 2013","DOI":"10.1016\/j.immuni.2013.03.003"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85 Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, <i>et al<\/i>.: M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than M1 cells <i>in vitro<\/i>. J Immunol 182:4415-4422, 2009","DOI":"10.4049\/jimmunol.0713732"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86 Pallasch CP, Leskov I, Braun CJ, Vorholt D, Drake A, <i>et al<\/i>.: Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell 156:590-602, 2014","DOI":"10.1016\/j.cell.2013.12.041"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87 Husson H, Carideo EG, Cardoso AA, Lugli SM, Neuberg D, <i>et al<\/i>.: MCP-1 modulates chemotaxis by follicular lymphoma cells. Br J Haematol 115:554-562, 2001","DOI":"10.1046\/j.1365-2141.2001.03145.x"},{"key":"88","unstructured":"88 Husson H, Freedman AS, Cardoso AA, Schultze L, Munoz O, <i>et al<\/i>.: CXCL13 (BCA-1) is produced by follicular lymphoma cells: role on the accumulation of malignant B cells. Br J Haematol 119:492-495, 2002"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89 Colombo MP, Trinchieri G: Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:155-168, 2002","DOI":"10.1016\/S1359-6101(01)00032-6"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90 Ansell SM, Geyer SM, Maurer MJ, Kurtin PJ, Micallef IN, <i>et al<\/i>.: Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin\u2019s lymphoma patients. Clin Cancer Res 12 (20 Pt 1):6056-6063, 2006","DOI":"10.1158\/1078-0432.CCR-06-1245"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91 Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, <i>et al<\/i>.: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350-354, 2006","DOI":"10.1038\/nature05115"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92 D\u2019Souza M, Fontenot AP, Mack DG, Lozupone C, Dillon S, <i>et al<\/i>.: Programmed death 1 expression on HIV-specific CD4<sup>+<\/sup> T cells is driven by viral replication and associated with T cell dysfunction. J Immunol 179:1979-1987, 2007","DOI":"10.4049\/jimmunol.179.3.1979"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93 Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, <i>et al<\/i>.: PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 80:11398-11403, 2006","DOI":"10.1128\/JVI.01177-06"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94 Mumprecht S1, Sch\u00fcrch C, Schwaller J, Solenthaler M, Ochsenbein AF: Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 114:1528-1536, 2009","DOI":"10.1182\/blood-2008-09-179697"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95 Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, <i>et al<\/i>.: Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114:1537-1544, 2009","DOI":"10.1182\/blood-2008-12-195792"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96 Jin HT, Anderson AC, Tan WG, West EE, Ha SJ, <i>et al<\/i>.: Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A 107:14733-14738, 2010","DOI":"10.1073\/pnas.1009731107"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97 Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, <i>et al<\/i>.: Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8<sup>+<\/sup> T cell dysfunction in melanoma patients. J Exp Med 207:2175-2186, 2010","DOI":"10.1084\/jem.20100637"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98 Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, <i>et al<\/i>.: Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207:2187-2194, 2010","DOI":"10.1084\/jem.20100643"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99 Rohatiner AZ, Gregory WM, Peterson B, Borden E, Solal-Celigny P, <i>et al<\/i>.: Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23: 2215-2223, 2005","DOI":"10.1200\/JCO.2005.06.146"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100 Khan KD, Emmanouilides C, Benson DM Jr, Hurst D, Garcia P, <i>et al<\/i>.: A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin\u2019s lymphoma. Clin Cancer Res 12:7046-7053, 2006","DOI":"10.1158\/1078-0432.CCR-06-1571"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101 Timmerman JM, Byrd JC, Andorsky DJ, Yamada RE, Kramer J, <i>et al<\/i>.: A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. Clin Cancer Res 18:5752-5760, 2012","DOI":"10.1158\/1078-0432.CCR-12-0456"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102 Mir MA, Maurer MJ, Ziesmer SC, Slager SL, Habermann T, <i>et al<\/i>.: Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. Blood 125:992-998, 2015","DOI":"10.1182\/blood-2014-06-583369"},{"key":"103","unstructured":"103 Maloney DG, Press OW, Braziel RM, Rimsza LM, Friedberg JW, <i>et al<\/i>.: A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin\u2019s lymphoma: SWOG 9800. Blood 98:843a, 2001 [Abstract 3502]"},{"key":"104","unstructured":"104 Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, <i>et al<\/i>. Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin\u2019s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 24:4143-4149, 2006"},{"key":"105","unstructured":"105 Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, <i>et al<\/i>.: Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus <sup>131<\/sup>iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 31:314-320, 2013"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106 Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, <i>et al<\/i>.: Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother 62:39-49, 2013","DOI":"10.1007\/s00262-012-1308-3"},{"key":"107","unstructured":"107 Fowler NH, Neelapu SS, Hagemeister FB, McLaughlin P, Kwak LW, <i>et al<\/i>.: Lenalidomide and rituximab for untreated indolent lymphoma: final results of a phase II study. Blood (ASH Annual Meeting Abstracts) 120:901, 2012 [Abstract]"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/56\/1\/56_1\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T01:38:12Z","timestamp":1656725892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/56\/1\/56_1\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":107,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.56.1","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}